Their role in alleviating HFD-induced hepatic steatosis, mediated via the LXRα–CYP7A1 axis, suggests a novel strategy to address the multifaceted challenges of MASLD [96]. This evidence concerns the gene NR1H3 and Hepatic steatosis.